117 results on '"Chanouzas, Dimitrios"'
Search Results
2. #3076 A UK parallel cohort study on renal ANCA associated vasculitis outcomes for avacopan exposed and matched unexposed cohorts
3. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)
4. Cocaine-induced granulomatosis with polyangiitis: an under-recognised condition
5. Cytomegalovirus modulation of the immune system in ANCA associated vasculitis
6. Cocaine-induced granulomatosis with polyangiitis—an under-recognized condition
7. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
8. The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis
9. MO250: COVID-19 Associated Collapsing Variant of Focal Segmental Glomerulosclerosis: A Case Series of 7 Patients from a Single UK Centre
10. Cytomegalovirus Infection Is A Risk Factor For Venous Thromboembolism In ANCA-Associated Vasculitis
11. Cocaine-induced granulomatosis with polyangiitis—an under-recognized condition.
12. Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney Disease
13. Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
14. Management of fatigue with physical activity and behavioural change support in vasculitis: a feasibility study
15. The longitudinal course of fatigue in antineutrophil cytoplasmic antibody–associated vasculitis
16. The Longitudinal Course of Fatigue in Anca Associated Vasculitis
17. What influences patient choice of treatment modality at the pre-dialysis stage?
18. Tubulo-interstitial disorders
19. Management of fatigue with physical activity and behavioural change support in vasculitis: a feasibility study.
20. The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody–associated Vasculitis
21. 292. UTILITY OF A ONE-STOP JOINT ENT-VASCULITIS CLINIC IN THE MANAGEMENT OF RELAPSING ANCA-ASSOCIATED VASCULITIS
22. 235. CYTOMEGALOVIRUS INFECTION IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN ANCA-ASSOCIATED VASCULITIS
23. How can we make renal medicine careers more appealing to UK trainees?
24. Glucocorticoid activation by 11β-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study
25. Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study
26. Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
27. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study
28. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals
29. Role of cytomegalovirus in the expansion of CD4+CD28– T cells in patients with ANCA-associated vasculitis: a proof-of-concept, randomised controlled trial
30. The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody–associated Vasculitis
31. Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
32. Glucocorticoid activation by 11β‐hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross‐sectional study.
33. Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an openlabel randomised controlled feasibility study.
34. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
35. FP152INCREASE IN ADVERSE EVENTS WITH PULSED METHYLPREDNISOLONE USED FOR INDUCTION OF REMISSION IN SEVERE ANCA ASSOCIATED VASCULITIS
36. FP020CD4+CD28- T-CELL EXPANSIONS IN ANCA-ASSOCIATED VASCULITIS ARE ASSOCIATED WITH ARTERIAL STIFFNESS
37. CD4+CD28– T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial
38. Evidence-based therapy for the ANCA-associated vasculitides: what do the trials show so far?
39. Timing of acute kidney injury — does it matter? A single-centre experience from the United Kingdom
40. Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis
41. Advances in Therapies for Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
42. What influences patient choice of treatment modality at the pre-dialysis stage?
43. 292. Utility of a one-stop joint ent-vasculitis clinic in the management of relapsing ANCA-associated vasculitis.
44. Additional file 4: of Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
45. Additional file 4: of Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
46. Additional file 1: of The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis
47. Additional file 1: of Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
48. Additional file 1: of The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis
49. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
50. Additional file 3: of Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.